Kyntra Bio
Antibody therapeutics (formerly FibroGen); roxadustat/Evrenzo retained
KYNB · Nasdaq · United States
Share price · KYNB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KYNB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-36.3%
- 10 Nov 2026-8.5%
Nothing announced by KYNB that day or the session before.
- 4 Nov 2026-8.1%
Nothing announced by KYNB that day or the session before.
- 23 Oct 2026-12.3%
Nothing announced by KYNB that day or the session before.
- 19 Oct 2026+8.9%
Nothing announced by KYNB that day or the session before.
- 16 Oct 2026-9.5%
Nothing announced by KYNB that day or the session before.
- 15 Oct 2026-3.7%
Nothing announced by KYNB that day or the session before.
- 14 Oct 2026-5.2%
Nothing announced by KYNB that day or the session before.
- 17 Sep 2026-6.7%
Nothing announced by KYNB that day or the session before.
- 2 Sep 2026+7.3%
Share of unusual movement by asset
For each asset, the share of KYNB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Roxadustat(Evrenzo) | Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney DiseaseMyelodysplastic Syndromes |
| Phase 1 | CD46Antibody–drug conjugate | Multiple Myeloma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | -$1.5M | $6.8M | $51M+ $41M short-term inv. | —-$4.0M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $3.7M | $7.6M | $37M+ $50M short-term inv. | $15M-$14M operating cash flow | report ↗ |
| 2025-Q3 | $1.1M | $1.2M | $118M | —-$1.9M operating cash flow | report ↗ |
| 2025-Q2 | $1.4M | $5.9M | $23M | $7.6M$13M operating cash flow | report ↗ |
| 2025-Q1 | $2.7M | $9.2M | $34M | —$2.7M operating cash flow | report ↗ |
| 2024-Q3 | $46M | $22M | $131M+ $0 short-term inv. | $17M-$8.4M operating cash flow | report ↗ |
| 2024-Q2 | $51M | $34M | $141M+ $0 short-term inv. | $16M-$40M operating cash flow | report ↗ |
| 2024-Q1 | $56M | $38M | $106M+ $72M short-term inv. | $33M-$59M operating cash flow | report ↗ |
| 2023-Q3 | $40M | $61M | $121M+ $130M short-term inv. | $64M-$85M operating cash flow | report ↗ |
| 2023-Q2 | $44M | $95M | $153M+ $183M short-term inv. | $88M-$111M operating cash flow | report ↗ |
| 2023-Q1 | $36M | $74M | $189M+ $167M short-term inv. | $77M-$102M operating cash flow | report ↗ |
| 2022-Q3 | $16M | $75M | $156M+ $253M short-term inv. | $92M-$52M operating cash flow | report ↗ |
| 2022-Q2 | $30M | $71M | $168M+ $270M short-term inv. | $73M-$33M operating cash flow | report ↗ |
| 2022-Q1 | $61M | $89M | $186M+ $242M short-term inv. | $63M-$8.5M operating cash flow | report ↗ |
| 2021-Q3 | $156M | $76M | $275M+ $212M short-term inv. | —$44M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $6.4M | $24M | $48M+ $41M short-term inv. | —-$4.8M operating cash flow | report ↗ |
Kyntra Bio reported full-year 2025 revenue of $6.44M, down 78.3% YoY, with R&D spend of $23.52M, down 75.4% YoY. Cash and equivalents were $47.87M, and the company reported net income of $183.45M for the year.
Management expects total cash, cash equivalents, investments, and accounts receivable of $109.4M to fund operations into 2028. The Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer is actively enrolling, with an interim analysis expected in the second half of 2026, and positive results from an investigator-sponsored study of FG-3246 combined with enzalutamide were presented at ASCO GU 2026. Kyntra Bio also submitted a pivotal Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes and holds FDA Orphan Drug Designation for that program, with a goal of starting the Phase 3 trial in the second half of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $30M | $96M | $50M+ $0 short-term inv. | $12M-$138M operating cash flow | report ↗ |
| 2023-FY | $148M | $283M | $114M+ $122M short-term inv. | $71M-$315M operating cash flow | report ↗ |
| 2022-FY | $141M | $297M | $156M+ $266M short-term inv. | $73M-$146M operating cash flow | report ↗ |
| 2021-FY | $235M | $387M | $171M+ $234M short-term inv. | $73M-$82M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($40K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-15 | Wettig Thane · director, CEO | Award / grant | 2,500 | $2.92 | $7K | Form 4 |
| 2026-10-01 | Singer Andrew E. · director | Award / grant (derivative) | 14,000 | — | — | Form 4 |
| 2026-09-06 | Wettig Thane · director, CEO | Tax withholding | 209 | $8.55 | $2K | Form 4 |
| 2026-09-06 | DeLucia David · Chief Financial Officer | Tax withholding | 22 | $8.55 | $188 | Form 4 |
| 2026-06-12 | Schoeneck James A · director | Award / grant (derivative) | 7,000 | — | — | Form 4 |
| 2026-06-12 | Kauffman Michael · director | Award / grant (derivative) | 7,000 | — | — | Form 4 |
| 2026-06-12 | EDWARDS JEFFREY L · director | Award / grant (derivative) | 7,000 | — | — | Form 4 |
| 2026-06-12 | Ho Maykin · director | Award / grant (derivative) | 7,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 1.0M shares ($6.3M, 25.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 400,000 | $2.7M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 156,607 | $1.1M |
| 3 | BlackRock, Inc. | 84,331 | $572K |
| 4 | TWO SIGMA INVESTMENTS, LP | 49,511 | $336K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 45,998 | $312K |
| 6 | HighTower Advisors, LLC | 39,744 | $269K |
| 7 | UBS Group AG | 27,591 | $187K |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 27,481 | $186K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 23,942 | $162K |
| 10 | Birchview Capital, LP | 22,566 | $153K |
| 11 | STATE STREET CORP | 20,284 | $138K |
| 12 | JANE STREET GROUP, LLC | 12,228 | $83K |
| 13 | ADAR1 Capital Management, LLC | 10,469 | $71K |
| 14 | GROUP ONE TRADING LLC | 4,492 | $30K |
| 15 | Vanguard Global Advisers, LLC | 1,424 | $10K |